Chinese clinical stage biotechnology company InventisBio Inc. announced on Monday the closing of a US$70 million series C round of financing led by Chinese private equity firm Advantech Capital and CMB International Capital, a wholly-owned subsidiary of China Merchants Bank (CMB).
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
